Drug Search Results

AVX-001

Alternative Names: avx-001, avx001, avx 001, akh-217, akh217, akh 217
Latest Update: 2024-04-01
Latest Update Note: PubMed Publication

Product Description

topical cytosolic phospholipase A2 inhibitor

Mechanisms of Action: Immunomodulator,PLA2 Modulator,TNF Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Avexxin AS
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Psoriasis|Dermatitis, Atopic|Keratosis, Actinic

Trial	Phase	Trial Status	Disease	Primary Completion Date	Probability of Success
COAKs	P2	Completed	Keratosis, Actinic	2022-03-11
COAKS	P2	Unknown status	Keratosis, Actinic	2022-03-01	32%
2019-000175-16	P2	Completed	Psoriasis	2019-11-15
2016-003013-96	P2	Completed	Dermatitis, Atopic	2016-12-29

Recent News Events

Date	Type	Title
04/01/2024	PubMed	Mobile health technologies in an interventional hybrid study on actinic keratosis: Results from an early phase randomized controlled trial investigating the safety and efficacy of a cytosolic phospholipase A2 inhibitor gel in photodamaged skin.
10/05/2022	PubMed	The Copenhagen Actinic Keratosis Study (COAKS). A decentralised clinical trial to evaluate tolerability, safety and efficacy of daily field-directed topical treatment with cytosolic phospholipase A(2) inhibitor, AVX001, in participants with actinic keratosis: protocol for a randomised controlled phase I/IIa trial.
09/01/2022	News Article	Global Actinic Keratosis Market to Surpass US$ 11,628.0 Million by 2030 - Coherent Market Insights
03/04/2022	News Article	Aravax Pty Ltd announces opening of IND for Phase 2 clinical trials of PVX108, a next-generation immunotherapy for the treatment of peanut allergy
10/02/2020	PubMed	cPLA2α Enzyme Inhibition Attenuates Inflammation and Keratinocyte Proliferation.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions